Xarelto, Equa Face Generic Debuts in Japan: December Listing
To read the full story
Related Article
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- First Generics of Equa Priced at 30% of Original Product
December 6, 2024
- Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
- Xarelto Copycats Earn Blessing, AG Might also Get on Board
August 19, 2024
- Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
REGULATORY
- MHLW Calls for Ongoing Nitrosamine Risk Controls after Self-Inspections
July 24, 2025
- 223 Health Damages Reported for Breyanzi in Japan: October-March
July 24, 2025
- MHLW Plans to Ease Clinical Trial Ad Rules, Eyes Notification by March-End
July 24, 2025
- New MHLW Drug Review Chief Aims to Dispel “Barrier” Perception, Pledges Active Engagement with Industry
July 23, 2025
- Healthcare Stakeholders Weigh Fallout after Ruling Bloc’s Election Setback
July 23, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…